Preoperative radiation therapy for soft tissue sarcoma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the use of neoadjuvant radiotherapy with a simultaneous integrated boost (SIB) for patients with soft tissue sarcoma (STS) who are candidates for surgical resection. The treatment involves administering radiation in 25 daily fractions, targeting both the tumor and areas at risk of micrometastatic spread. The primary goal is to evaluate the effectiveness of this approach in improving surgical outcomes, while secondary objectives include assessing treatment outcomes and potential toxicity. The study will enroll patients with newly diagnosed or locoregional recurrent STS.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients aged ≥ 18 years
* Confirmed histological diagnosis of soft tissue sarcoma
* Candidate for conservative surgery
* Performance status ≤ 1 according to WHO (or ≥ 70 according to KPS) before starting the treatment in the office.

Exclusion Criteria:

* Previous radiotherapy at the same site
* Candidate for Surgical Amputation
* Patients with comorbidities for collagen diseases
* Psychiatric disorders that may preclude obtaining the informed consent

Where it's running

• AOU Careggi
  Florence, Fi, Italy Recruiting

Study contacts

• Principal investigator: lorenzo livi, Dr — AOU Careggi
• Study coordinator: Marta Pacinico
• Email: marta.pacinico@unifi.it
• Phone: 0557947192

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• 68Ga-HX01 PET/CT Imaging in Soft Tissue Sarcoma patients

  This study tests whether a 68Ga-HX01 injection can help PET/CT imaging better characterize soft tissue sarcoma in adults who have exhausted standard treatments or have no good options.

  Recruiting Phase 2 Hexin (Suzhou) Pharmaceutical Technology Co., Ltd · Wuhan, Hubei · NCT07920835

• Zemetostat plus Anlotinib for SWI/SNF-deficient Head and Neck Soft Tissue Sarcoma

  This trial tests whether zemetostat plus anlotinib can help people with recurrent or metastatic head-and-neck soft tissue sarcoma that has SWI/SNF complex deficiency after standard therapy fails.

  Recruiting Phase 2 Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University · Shanghai, Shanghai Municipality · NCT07917949

• Entinostat for pediatric soft tissue sarcoma with PAX abnormalities

  This study tests entinostat, alone or with chemotherapy, in children whose soft tissue sarcomas have PAX-family gene abnormalities to see if it can help shrink tumors or slow progression.

  Recruiting Phase 1 Beijing Tongren Hospital · Beijing, Beijing Municipality · NCT07888114

• Methionine-Reduced Diet in Solid Tumors (early-phase)

  A small pilot study will test whether a methionine-reduced diet can change blood levels in adults with various solid tumors who are receiving standard cancer therapy.

  Recruiting Early Phase 1 University of California, Irvine · Orange, California · NCT07628634

• Preoperative Immunonutrition for bone and soft tissue sarcoma patients

  This study tests whether a short course of an oral nutrition supplement before surgery can help patients with bone or soft tissue sarcomas recover better after major tumor-related surgery.

  Recruiting St. Anne's University Hospital Brno, Czech Republic · Brno · NCT07609329

• Adaptive Proton Therapy for Pediatric Solid Tumors and Hodgkin Lymphoma

  This study tests a regular imaging approach to see if proton therapy plans for children with solid tumors or Hodgkin lymphoma should be updated during treatment.

  Recruiting St. Jude Children's Research Hospital · Memphis, Tennessee · NCT07514819

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.